4-(溴甲基)哌啶甲酸苄酯 | 159275-17-9

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(溴甲基)哌啶甲酸苄酯
• 中文别名: 1-Cbz-4-(溴甲基)哌啶；N-CBZ-4-溴甲基哌啶；4-(溴甲基)哌啶-1-羧酸苄酯；1-CBZ-4-溴甲基哌啶
• 英文名称: benzyl 4-(bromomethyl)tetrahydro-1-(2H)-pyridinecarboxylate
• 英文别名: benzyl 4-(bromomethyl)piperidine-1-carboxylate；benzyl 4-(bromomethyl)piperidine-N-carboxylate；benzyl 4-bromomethylpiperidine-1-carboxylate；4-Bromomethyl-piperidine-1-carboxylic acid benzyl ester；4-bromomethylpiperidine-1-carboxylic acid benzyl ester
• CAS: 159275-17-9
• 化学式: C₁₄H₁₈BrNO₂
• 分子量: 312.206
• InChiKey: XJHKDSZGAWXUTB-UHFFFAOYSA-N

物化性质

• 熔点：
  68 °C
• 沸点：
  403.4±28.0 °C(Predicted)
• 密度：
  1.356±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi,C
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 安全说明：
  S26,S36/37/39
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P280,P301+P310+P330+P331,P303+P361+P353+P310,P304+P340+P310,P305+P351+P338+P310,P363,P405,P501
• 危险品运输编号：
  1759
• 危险性描述：
  H314

SDS

Name:	Benzyl 4-(bromomethyl)tetrahydro-1(2h)-pyridinecarboxylate 97% Material Safety Data Sheet
Synonym:	4-Bromomethylpiperidine-1-carboxylic acid benzyl este
CAS:	159275-17-9

Section 1 - Chemical Product MSDS Name:Benzyl 4-(bromomethyl)tetrahydro-1(2h)-pyridinecarboxylate 97% Material Safety Data Sheet
Synonym:4-Bromomethylpiperidine-1-carboxylic acid benzyl este

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
159275-17-9	Benzyl 4-(bromomethyl)tetrahydro-1(2H)	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 159275-17-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: off-white
Odor: sweetish odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 67 - 68 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H18BrNO2
Molecular Weight: 312

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, hydrogen bromide, acrid smoke and fumes, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 159275-17-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Benzyl 4-(bromomethyl)tetrahydro-1(2H)-pyridinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 159275-17-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 159275-17-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 159275-17-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  1-Cbz-4-羟甲基哌啶	benzyl 4-(hydroxymethyl)piperidine-N-carboxylate	122860-33-7	C14H19NO3	249.31
  N-Cbz-哌啶-4-羧酸	1-benzyloxycarbonylpiperidine-4-carboxylic acid	10314-98-4	C14H17NO4	263.293
  1-Cbz-4-MS-甲基-哌啶	benzyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate	159275-16-8	C15H21NO5S	327.401

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	benzyl 4-{[bis(tert-butoxycarbonyl)amino]methyl}piperidine-N-carboxylate	566905-91-7	C24H36N2O6	448.56
  ——	(2S)-3-(1-benzyloxycarbonyl-4-piperidyl)-2-(tert-butoxycarbonylamino)propanoic acid	368866-15-3	C21H30N2O6	406.479

反应信息

• 作为反应物：
  描述：

  4-(溴甲基)哌啶甲酸苄酯 在 盐酸 、 正丁基锂 、 lithium hydroxide monohydrate 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 7.0h， 生成 (2S)-3-(1-benzyloxycarbonyl-4-piperidyl)-2-(tert-butoxycarbonylamino)propanoic acid
  参考文献：
  名称：

  [EN] LMP7 INHIBITORS
  [FR] INHIBITEURS DE LMP7

  摘要：

  公开号：

  WO2015195950A8
• 作为产物：
  描述：

  1-Cbz-4-MS-甲基-哌啶 在 lithium bromide 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 生成 4-(溴甲基)哌啶甲酸苄酯
  参考文献：
  名称：

  Phosphonic acid derivatives

  摘要：

  一种用于医学治疗高脂血症的膦酸衍生物，其通式如下（I）或其药学上可接受的盐：代表性的根据本发明的化合物示例为下式所示：

  公开号：

  US05719303A1

文献信息

• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• [EN] PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] ANTAGONISTES DE RECEPTEUR DE LA PROSTAGLANDINE D2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2005100321A1

  公开（公告）日：2005-10-27

  Disclosed herein are compounds represented by Structural Formula: (I) and (I-A). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply 'CRTH2' for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-A) are defined herein.

  本文披露了由结构式(I)和(I-A)表示的化合物。还披露了利用这些化合物抑制称为趋化剂受体同源分子表达在Th2上的G蛋白偶联受体，简称为'CRTH2'，用于治疗炎症性疾病。结构式(I)和(I-A)中的变量在此处被定义。
• Triazol Derivatives Useful For The Treatment of Diseases
  申请人：Jones Lyn Howard

  公开号：US20100010040A1

  公开（公告）日：2010-01-14

  The invention relates to compounds of formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in particular inflammatory, allergic and respiratory diseases, disorders and conditions.

  这项发明涉及到式（1）的化合物，以及用于制备、用于制备的中间体、含有这些衍生物的组合物以及这些衍生物的用途的过程。根据本发明的化合物在许多疾病、紊乱和状况中具有用途，特别是在炎症性、过敏性和呼吸系统疾病、紊乱和状况中。
• Amidine compounds
  申请人：Japan Tobacco Inc.

  公开号：US06562828B1

  公开（公告）日：2003-05-13

  A compound of the formula [I] wherein R1, R2 and R3 are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention, a salt thereof and a prodrug thereof are useful as factor Xa inhibitor and blood coagulation inhibitor, and are useful for the prophylaxis and/or treatment of diseases caused by blood coagulation or thrombus.

  其中R1、R2和R3相同或不同，且每个都是氢原子，其中每个符号如规范中定义，其盐或前药。本发明的化合物及其盐和前药可用作因子Xa抑制剂和抗凝血剂，对于预防和/或治疗由血液凝固或血栓引起的疾病有用。
• Synthesis and Structure−Activity Relationships of Novel Selective Factor Xa Inhibitors with a Tetrahydroisoquinoline Ring
  作者：Hiroshi Ueno、Katsuyuki Yokota、Jun-ichi Hoshi、Katsutaka Yasue、Mikio Hayashi、Yasunori Hase、Itsuo Uchida、Kazuo Aisaka、Susumu Katoh、Hidetsura Cho

  DOI：10.1021/jm058160e

  日期：2005.5.1

  A series of novel 2,7-disubstituted tetrahydroisoquinoline derivatives were designed and synthesized. Among these derivatives, compounds 1 and 2 exhibited potent inhibitory activity against factor Xa (FXa) and good selectivity with respect to other serine proteases (thrombin, plasmin, and trypsin). In addition, compound 2 exhibited potent anti-FXa activity after intravenous and oral administration

  设计并合成了一系列新颖的2,7-二取代的四氢异喹啉衍生物。在这些衍生物中，化合物1和2对Xa因子（FXa）表现出有效的抑制活性，并且对其他丝氨酸蛋白酶（凝血酶，纤溶酶和胰蛋白酶）具有良好的选择性。此外，化合物2在食蟹猴静脉和口服给药后均显示出有效的抗FXa活性，在0.1、0.3和1 mg kg（-1）h（-1）的大鼠模型中显示出剂量依赖性的抗血栓形成作用。静脉血栓形成，并以0.1 mg kg（-1）h（-1）的剂量显着减少了大脑中动脉闭塞模型中脑梗塞的大小。这些结果表明，化合物2（JTV-803）可能同时用作静脉和动脉抗血栓形成剂。